Please select the option that best describes you:
What is your approach for adjuvant endocrine therapy in a female with HR+ breast cancer with history of provoked DVT while on OCPs?
Would your approach differ if patient is premenopausal or postmenopausal?
Answer from: Medical Oncologist at Community Practice
In a postmenopausal female with HR+HER2- breast cancer and a history of DVT on OCPs, I would recommend adjuvant endocrine therapy with an aromatase inhibitor and not tamoxifen. This is based on improved efficacy for aromatase inhibitors compared to tamoxifen in this population, and VTE risk associat...
Sign in or Register to read more